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Phyllodes tumorPhyllodes tumors (PTs) account for b3% of ﬁbroepithelial breast lesions and for 0.3% to 1.0% of primary breast tu-
mors. They occur predominantly in middle-aged women (mean age range, 40–50 years). PTs can be categorized
into benign, borderline, and malignant; the ﬁrst 2 categories are distinguished only by degree of cellular atypia
and mitotic activity. Malignant PTs are more frequent among persons of Hispanic ethnicity, especially those
born in Central America or South America. Heterologous sarcomatous elements may be present in malignant
PTs, predominantly liposarcoma and rarely ﬁbrosarcoma, rhabdomyosarcoma, leiomyosarcoma, osteosarcoma,
and chondrosarcoma. Breast angiosarcoma (BA) is a rare heterologous, sarcomatous element that may arise sec-
ondary tomalignant PT.We report a 47-year-oldwomanwith nohistory of previous surgery or radiation therapy
who presented to the emergency department with a painful right breast mass. She admittedly noticed the right
breast mass for many years; however, recently it increased in size. Mammography and ultrasonography identi-
ﬁed a partially cystic mass. Core needle biopsy showed dense hyalinized ﬁbrous tissue with old blood clots, sug-
gestive of infarcted ﬁbroadenoma. The patient received antibiotics and analgesics; however, she reported
intractable pain and a worsening skin rash of her right breast. Chest computed tomography and magnetic reso-
nance imaging showed a doubling in mass size, with pectoralis major muscle involvement. Incisional biopsy
showed malignant PT with heterologous high-grade angiosarcoma. The diagnosis of angiosarcoma was con-
ﬁrmed through immunoreactivity for CD31, FLI1, and ERG immunostains.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Phyllodes tumors (PTs) are rare ﬁbroepithelial lesions and are con-
sidered true neoplasms [1,2]. They historically have been given many
names that are misleading and unhelpful. Thus, the term cystosarcoma
phyllodes is no longer used [2]. The name phyllodes tumor is derived
from the Greek word phyllos, meaning leaf. Gross examination shows
that PTs can have variable sizes ranging from a few centimeters to
20 cm (mean, 4–5 cm) [2]. Benign PTs are well deﬁned and often lobu-
lated, whereas borderline andmalignant PTs are ill deﬁned [2,3]. Micro-
scopic examination shows cellular stroma lined by an epithelial and
myoepithelial bilayer, forming a leaﬂike structure. A focally inﬁltrative
border can be seen in borderline PT [2,4]. Malignant PTs show a promi-
nent inﬁltrative border, unequivocal sarcomatous areas, and stromal
overgrowth [2,5]. Heterologous sarcomatous elements occasionally
may be present in malignant tumors [2]. By comparison, angiosarcoma
is a rare heterologous sarcomatous element that could arise secondary
to malignant PT [2,6].sonance imaging; PT, phyllodes
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16/j.ehpc.2016.07.002Breast angiosarcomas (BAs) are rare malignant tumors arising from
endothelial cells or their precursors [7]. They comprise about 0.05% of all
breast cancers, but they are the second most common mesenchymal
malignancy of the breast after malignant PT [8]. Primary or idiopathic
BAs are more common in young premenopausal women and are pres-
ent as a deep breast mass [7,8]. Secondary BAs develop in older post-
menopausal patients, frequently 5 to 6 years after radiotherapy, and
they are more superﬁcial and usually present as a rash or bruising
[9,10]. Radiation treatment of breast cancer has increased the risk of
BA of the skin by 9 times [10]; however, radiation treatment for
Hodgkin disease increased the risk of breast cancer but not of BA [4].
After breast and axillary surgery, the armwith complicated lymphedema
at the surgery site has increased risk of BA of the skin, known as Stewart-
Treves syndrome [8–11].
We describe a case of high-grade angiosarcoma secondary to malig-
nant PT in a middle-aged woman.
2. Case presentation
A47-year-oldwomanwith nohistory of alcohol or tobacco use or ra-
diation exposure presented to the emergency department with a pain-
ful right breast mass. She admitted noticing a right breast mass for
many years; however, recently it increased in size. The mass invadedthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Fig. 1. The right breast with skin changes. A, Skin changes with ecchymosis. B, Erythema-
tous plaques and surface ulcerations.
Fig. 2. Imaging of the right breast. A, Ultrasonography showing heterogeneous, partially
cystic mass. B, Chest computed tomography scan showing the heterogeneous mass. C,
Magnetic resonance imaging of the chest showing the mass with skin and pectoralis
major muscle involvement.
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ed the right pectoralis muscle.
2.1. Radiologic evaluation
Mammography and ultrasonography identiﬁed a partially cystic
mass measuring 4.8 × 6.6 × 5.9 cm (Fig. 2A). Ultrasound-guided aspira-
tion revealed 35mL of old blood, presumed as a hematoma. Core needle
biopsy showed dense, hyalinized ﬁbrous tissue with old blood clots,
suggestive of an infarcted ﬁbroadenoma. The patient was treated with
antibiotics and analgesics. However, the skin ecchymosis and erythema
were increasing and covering almost the entire right breast, and the
breast pain was intractable. The patient had chest computed tomogra-
phy andmagnetic resonance imaging (MRI) at 2months after her initial
presentation. The imaging showed multicystic complex, heteroge-
neously enhancing mass in the right breast measuring 11.3 × 14
× 10 cm—double the size seen in the initial ultrasonography examina-
tion 2 months previously (Fig. 2B and C). The patient underwent
incisional biopsy, which showed malignant PT with heterologous
angiosarcoma.
2.2. Gross examination
The specimenwas a 6.5 × 3.7 × 3.5-cm, 115-g right breast lumpecto-
my with a ragged cut surface. It consisted mostly of hemorrhagic tissue
with ill-deﬁned cystic lesion that had hemorrhagic contents. No skin or
nipple was identiﬁed.
2.3. Microscopic examination
Multiple sections demonstrated a ﬁbroepithelial lesion with exten-
sive infarction and an associated malignant epithelioid and spindle cellPlease cite this article as: G. Tranesh, A. Nassar,Malignant phyllodes tumor
Case Reports (2016), http://dx.doi.org/10.1016/j.ehpc.2016.07.002proliferation involving the stromal component. The latter proliferation
showed high-grade cytologic atypia with numerous mitoses and areas
of extensive necrosis. Vague areas of vasoformative growth were seen,
as well as prominent hemorrhage (Fig. 3A–D).
The differential diagnosis was between angiosarcoma secondarily
involving a PT and malignant PT with heterologous angiosarcoma.
Given the intimate association of angiosarcoma with the stromalof the breastwith heterologous high-grade angiosarcoma,Human Path
Fig. 3. Phyllodes tumor. A, Stromal overgrowth. B, Heterogeneity with inﬁltrative borders. C, Heterogeneity with angiosarcomatous areas. D, Angiosarcoma showingmarked cytologic and
nuclear atypia with solid sheets of spindle cells and extravasation of red blood cells.
3G. Tranesh, A. Nassar / Human Pathology: Case Reports xxx (2016) xxx–xxxcomponent of theunderlyingﬁbroepithelial lesion, the latter interpreta-
tion was favored, with high-grade morphologic characteristics.
2.4. Immunohistochemistry
Evaluation with immunohistochemical stains (Table 1) was per-
formed to detect the nature of the tumor cells. The angiosarcomatous
area tested positive for CD31, FLI, and ERG (Fig. 4A–C) and negative
for cytokeratin AE1/AE3, CAM 5.2, and p63.
3. Discussion
PTs are ﬁbroepithelial tumors composed of epithelial elements that
project into a hypercellular stroma in a leaﬂike manner [2,4]. They
were ﬁrst considered a kind of breast sarcoma, but their relatively be-
nign behavior has led to their being considered separately [2,4]. The
World Health Organization has subclassiﬁed PTs into benign, borderline,
and malignant according to stromal cellularity, cellular pleomorphism,
and tumor margins; stromal pattern; and heterologous stromal distri-
bution [2,4]. These different elements are explained in Table 2 [4].
The majority of PT tumors (up to 60%) are benign and composed of
cellular stroma formed from spindled cells, which are somewhatTable 1
Detailed information about used immunohistochemical Stains.
Antibody Clone Supplier Dilu
AE1/3 AE1/AE3 Dako Pred
CAM 5.2 CAM 5.2 Becton Dickinson 1:21
p63 4A4 Ventana Medical Systems Pred
CD 31 JC/70 A Lab Vision Corp. Pred
FLI-1 G146–254 BD Pharmingen 1/50
ERG 9FY
Biocare Medical Inc.
1/25
Abbreviations: BRD, background-reducing diluent; CC1, cell-conditioning solution.
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high-power ﬁelds) [2,4]. Occasionally, bizarre pleomorphic stromal
cellsmay be seen, but they should not lead to the diagnosis ofmalignant
PT in the absence of other distinguishing features. The lesion margin is
usually relatively well deﬁned, with no stromal overgrowth, deﬁned
as absence of epithelial elements within the ﬁelds of view at original
magniﬁcation ×4 and ×10 ocular [2,4].
At the other end of the PT spectrum are lesions composed of
markedly atypical stromal cells with abundant mitoses (N10 per 10
high-power ﬁelds) in which the stroma has outgrown the epithelial
component and inﬁltrates the adjacent parenchyma [2,4]. Occasionally,
speciﬁc heterologous sarcomatous elements may be seen, such as pre-
dominantly liposarcoma and, rarely, osteosarcoma, chondrosarcoma, ﬁ-
brosarcoma, or rhabdomyosarcoma. Such malignant PTs account for
approximately 20% of all cases [4]. Malignant PTs are more common in
the Hispanic population, especially persons born in Central America or
South America [4]. Patients who have tumors with an inﬁltrating
tumor margin, severe stromal overgrowth, atypia, and cellularity are
at high risk for metastases [12].
Our current case is the fourth case in the literature of angiosarcoma
developing in a clinical setting of PT (Table 3). Two previously reported
cases occurred in a clinical setting of recurrent PTs (1 benign and 1tion Antigen retrieval method Platform
ilute High pH Dako/Envision Flex
High pH Dako/Envision Flex
ilute CC1 56 min OptiView DAB
ilute High pH FLEX + MX
BRD CC1 mild 30 min OptiView DAB
BRD CC1 mild 32 min OptiView + OptiView AMP
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Fig. 4.Angiosarcoma conﬁrmed by immunoreactivity to immunostains. A, CD31 immuno-
stain. B, ERG immunostain. C, FLI1 immunostain.
Table 2
WHO histologic criteria for classiﬁcation of the different PTs.
WHO classiﬁcation Benign PT
Stromal cellularity Modest
Cellular pleomorphism Little
Mitoses Few, if any
Margins Well circumscribed (pushing border)
Stromal pattern Uniform stromal distribution
Heterogeneous stromal distribution Rare
Overall average distribution, % 60
Abbreviations: HPF, high-power ﬁeld; PT, phyllodes tumor; WHO, World Health Organization.
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Case Reports (2016), http://dx.doi.org/10.1016/j.ehpc.2016.07.002malignant) [13,14]. Three of the 4 angiosarcomas were high grade; 1
angiosarcoma showed a low-grade tumor occurring in association
with recurrent benign PT [13–15].
The mammographic picture of BA is nonspeciﬁc. It usually presents
as an ill-deﬁned, noncalciﬁed mass or with focal asymmetry as the
most commonﬁnding. Yang et al. [16] found that 19% of patients had tu-
mors not visible on mammography but visible with sonography and
MRI. Ultrasonography is used for mass conﬁrmation when a palpable
abnormality is found. Masses may be circumscribed or ill deﬁned
[16,17]MRI of BA shows a heterogeneousmasswith low signal intensity
on T1-weighted images, but signal intensity is high in images that are
heavily T2-weighted [16,17]
Gross examination of BA usually shows an ill-deﬁned hemorrhagic
mass, ranging from1 cm to 20 cm(mean size, 5 cm) [7,8]. Histologically,
the tumor consists of abnormal blood vessels in the dermis and breast
stroma [7–9]. Blood vessels are increased in number and form complex
anastomosing channels. Borders are inﬁltrative and not well
circumscribed. Necrosis and blood lakes may be present [7,8]. Endothe-
lial cells show enlarged, pleomorphic nuclei with frequent mitotic ﬁg-
ures [7,8]. Usually, the tumor cells are positive for vascular markers,
includingCD31, CD34, ERG, and FLI-1 [18]. Tumor cells are typically neg-
ative for cytokeratin and EMA [18].
Treatment of BAs is surgical removal with wide margins, and most
patients requiremastectomy to achieve this goal. Chemotherapy and ra-
diation therapy are also used but have uncertain beneﬁts [8–10]. Many
patients with BA have distant metastasis—lungs being the most com-
mon site, followed by liver, bone, and contralateral breast. Median
recurrence-free survival time is about 3 years; overall survival is
b6 years [19].
Primary BA typically follows an aggressive course, with a recurrence
rate of approximately 25%, a metastatic rate of 60% (median, 34 months
after diagnosis), and, in 1 large series, a 5-year mortality rate of about
50% [8]. Axillary lymph node involvement is exceptional. About one-
third of the lesions are high grade. Importantly, in 1 series, patient out-
come has not shown a correlation with histologic grade of the
angiosarcoma; therefore, some experts have questioned the value of
grading such lesions [8].
Surgery is the cornerstone of treatment of primary breast
angiosarcomas while the role of both chemotherapy and radiation is
still controversial. Biswas et al. [9] showed, in a study of 8 patients iden-
tiﬁed as having histologically conﬁrmed diagnosis of angiosarcoma of
the breast, 7 patients (87%) had a history of prior radiation to the breast,
and the other patient had primary de novo angiosarcoma. Median over-
all survival was 37.4 months (range, 8.7–92.8 months); relapse-free
survival was 17.9 months (range, 2.5–69.4 months) [9].
Patients with radiation-associated angiosarcomas have a poor prog-
nosis, with an overall 5-year survival rate of approximately 40% [10].
Among these tumors, 80% are high grade, but the outcome does not ap-
pear to be associatedwith tumor grade [8]. Surgical excision is themain
therapeutic modality [8,9].Borderline PT Malignant PT
Modest Marked
Moderate Marked
Intermediate Numerous, ≥10/HPF
Focally inﬁltrative Inﬁltrative
Heterogeneous stromal distribution Marked stromal overgrowth
Rare Not uncommon
20 20
(Data from Lekhani at al [4].)
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Table 3
Three published angiosarcoma cases in comparison with the present case.
Case Authors/year Age, y Sex Size, cm Recurrent Angiosarcoma grade Phyllodes tumor grade IHC
1 Mamoon et al./2009 [14] 70 F 5.5 Yes Low Benign CD31, CD34
2 Kumar et al./2012 [13] 22 F 8.0 Yes High Malignant CD31, CD34
3 Costa et al./2012 [15] 83 F 15.0 No High Borderline ND
Present Tranesh et al./2016 47 F 6.5 No High Malignant CD31, ERG, FLI-1, AE1/3, CAM5.2, p63
Abbreviations: F, female; IHC, immunohistochemistry; ND, not done.
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